- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01909908
ECM and Blood Components for Wound Healing
September 28, 2016 updated by: Cook Group Incorporated
Treatment of Chronic Wounds Using Extracellular Matrix-Based Devices and the Patient's Own Blood Components
The Extracellular Matrix (ECM) and Blood Components for Wound Healing feasibility study is a clinical trial approved by Health Canada to study the safety of extracellular matrix (ECM) and autologous blood products in wound healing.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
2
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3A 1R9
- Health Sciences Centre
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Type 1 or Type 2 diabetes, and/or venous insufficiency to the affected leg
- Ulcer has been present between 12 and 52 weeks
- Ulcer is less than 40 cm2 in area
Exclusion Criteria:
- Less than 18 years of age
- Pregnant or planning to become pregnant during the study period
- Simultaneously participating in another investigational drug or device study
- Unable or unwilling to comply with the weekly study follow-up schedule or off-loading regimen
- Patient or legal representative refuses to sign the EC-approved informed consent form
- Known allergy to pig or porcine products
- Additional criteria may apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ECM in Saline
|
ECM in saline applied to wound
|
Active Comparator: Blood Products
|
Autologous blood product applied to wound, with saline cleanse on alternating weeks
|
Experimental: ECM in Blood Products
|
Alternating treatments of ECM in saline and ECM in autologous blood products, applied to wound
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of adverse events
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: John Embil, MD, FRCPC, University of Manitoba
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2013
Primary Completion (Actual)
June 1, 2016
Study Completion (Actual)
September 1, 2016
Study Registration Dates
First Submitted
July 25, 2013
First Submitted That Met QC Criteria
July 26, 2013
First Posted (Estimate)
July 29, 2013
Study Record Updates
Last Update Posted (Estimate)
September 29, 2016
Last Update Submitted That Met QC Criteria
September 28, 2016
Last Verified
September 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12-014
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ulcer
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownBleeding Gastric Ulcer | Bleeding Duodenal UlcerChina
-
Groupe Hospitalier Paris Saint JosephCompletedUlcer, Leg | Ulcer AlgicFrance
-
Paul EdwardsCompletedDecubitis UlcerUnited States
-
King Chulalongkorn Memorial HospitalCompletedGastric Ulcer Induced by Anti-platelet Agent | Duodenal Ulcer Induced by Anti-platelet AgentThailand
-
The Catholic University of KoreaSt Vincent's Hospital; Bucheon St. Mary's HospitalUnknown
-
Assistance Publique - Hôpitaux de ParisRecruitingVenous Ulcer | Diabetic Ulcer | Sickle Cell Ulcer | Post-partum Women | Mixed UlcerFrance
-
AstraZenecaCompletedGastric Ulcer | Duodenal UlcerUnited States, Bulgaria, Czech Republic, Korea, Republic of, Russian Federation, South Africa, Philippines, Poland, Romania, Finland, Norway, Canada, Mexico, Argentina, Australia, Germany, Portugal, Slovakia, Thailand, Indonesia
-
Zagazig UniversityCompletedUlcer Foot | Chronic Skin Ulcer | Non-Healing Ulcer of SkinEgypt
-
Smith & Nephew, Inc.TerminatedSurgical Incision | Pressure Ulcer | Ulcer Foot | Wound Dehiscence | Ulcer, Leg | Ulcer VenousUnited Kingdom, Germany
-
Skilled Skin S.L.CompletedSurgical Wound | Diabetic Foot Ulcer | Skin Lesion | Pressure Ulcer | Hematoma | Venous Ulcer | Ischemic Ulcer | Arterial Ulcer | Diabetic Neuropathic Ulcer | Traumatic Ulcer | Ulcer, SkinSpain
Clinical Trials on ECM
-
Inova Health Care ServicesCorMatrix Cardiovascular, Inc.TerminatedCoronary Artery DiseaseUnited States
-
CorMatrix Cardiovascular, Inc.Completed
-
CorMatrix Cardiovascular, Inc.Recruiting
-
Kerecis Ltd.CompletedPunch Biopsy Wounds | Healing TimesIceland
-
Aziyo Biologics, Inc.Withdrawn
-
Aziyo Biologics, Inc.Completed
-
Aziyo Biologics, Inc.CompletedPeripheral Vascular Disease
-
SerenaGroup, Inc.RecruitingDiabetic Foot UlcerUnited States
-
Cook Biotech IncorporatedRecruitingWounds and Injuries | Surgical Wound | Wound Heal | WoundUnited Kingdom
-
Harvard School of Public Health (HSPH)Georgetown University; World Bank; Estonia Health Insurance FundCompletedMulti-morbidity | Non-communicable DiseasesEstonia